In the future, a combination of biomarkers may be used: antigen density (quantified by imaging uptake or histology) could predict the intensity of the TCE response, while immune contexture markers (such as baseline T-cell infiltration or interferon-gamma gene signatures) might predict how readily the TCE-redirected T-cells can infiltrate and function in a given tumor [26]. The gene discussed is IFNG; the disease is neoplasm.